Food and Drug Administration, HHS.
The Food and Drug Administration (FDA) is amending the animal drug regulations to remove those portions that reflect approval of two new animal drug applications (NADAs) held by EVSCO Pharmaceuticals, an Affiliate of IGI, Inc. In a notice published elsewhere in this issue of the Federal Register, FDA is withdrawing approval of these NADAs.
This rule is effective August 27, 2001.Start Further Info
FOR FURTHER INFORMATION CONTACT:
Pamela K. Esposito, Center for Veterinary Medicine (HFV-210), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-5593.End Further Info End Preamble Start Supplemental Information
EVSCO Pharmaceuticals, an Affiliate of IGI, Inc., Box 209, Harding Hwy., Buena, NJ 08310, has requested that FDA withdraw approval of NADA 32-984 for Cerumite (chloramphenicol, prednisolone, tetracaine, and squalane) Start Printed Page 42731topical suspension, and NADA 55-005 for Liquichlor with Cerumene (squalane, pyrethrins, and piperonyl butoxide) topical suspension because the products are no longer manufactured or marketed. As provided below, the animal drug regulations are amended to reflect the withdrawal of approval of these NADAs by removing 21 CFR 524.390c and 524.2140.
In a notice published elsewhere in this issue of the Federal Register, FDA is withdrawing approval of these NADAs.
This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.Start List of Subjects
List of Subjects in 21 CFR Part 524End List of Subjects Start Amendment Part
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine,End Amendment Part Start Part
PART 524—OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGSEnd Part
1. The authority citation for 21 CFR part 524 continues to read as follows:
2. Section 524.390c Chloramphenicol-prednisolone-tetracaine-squalane topical suspension is removed.
3. Section 524.2140 Squalane, pyrethrins and piperonyl butoxide is removed.Start Signature
Dated: August 6, 2001.
Stephen F. Sundlof,
Director, Center for Veterinary Medicine.
[FR Doc. 01-20573 Filed 8-14-01; 8:45 am]
BILLING CODE 4160-01-S